This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
At a median follow-up of 36 months, patients with acute thrombotic thrombocytopenic purpura displayed impaired quality of life compared with the general population.
The FDA has approved the supplemental Biologics License Application for Nplate (romiplostim; Amgen) to expand treatment to newly diagnosed adult patients with immune thrombocytopenia.
Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis
Current guidelines recommend 5 weeks of postoperative prophylactic anticoagulation, but a new study suggests the duration of this treatment ought to be extended.
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Researchers found a low incidence of thrombotic events in patients receiving ibrutinib, though some patients still experienced bleeding.
Researchers found that most instances of venous thromboembolism occurred while patients were receiving prophylaxis.
Splenectomy is often administered as third- or fourth-line therapy, but earlier administration may mitigate treatment-related complications.
Stroke occurred in no patients with normal ADAMTS13 activity but did occur in 27.6% of patients with ADAMTS13 activity below 70%, the cutoff for normal activity.
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
Researchers assessed the efficacy of a target international normalized ratio of 1.8 compared with the standard of 2.5 for thromboprophylaxis following arthroplasty.
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
Common causes of extreme thrombocytosis differed in inpatient and outpatient settings, according to a review of 44,490 patient records.
Eltrombopag and romiplostim demonstrated superior response compared with rituximab for persistent adult immune thrombocytopenia.
Rates of recurrence and bleeding were similar between the 3 treatments assessed, but rivaroxaban demonstrated lower mortality rates.
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Reinitiation of oral anticoagulant therapy may be warranted for some patients with atrial fibrillation who have a high risk of bleeding.
Researchers assessed whether loss of von Willebrand factor high-molecular-weight multimers was predictive of morbidity in thrombotic thrombocytopenic purpura.
Researchers interviewed clinicians and patients to develop a conceptual model of congenital thrombotic thrombocytopenic purpura.
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Incidences of recurrent thromboembolism and major bleeding did not significantly differ between patients receiving DOACs and patients receiving warfarin.
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
A higher proportion of black patients and female patients with thrombotic thrombocytopenic purpura had coexisting connective tissue disorders.
Researchers assessed incidence of recurrent thromboembolism and major bleeding in patients with cancer and incidental pulmonary embolism.
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
Utilizing a PLASMIC score-based algorithm may reduce treatment costs by reducing overutilization of therapeutic plasma exchange and expert consultations.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Similar rates of thrombotic events occurred in patients with FXII deficiency and unaffected controls.
Researchers described 2 patients with refractory thrombotic thrombocytopenic purpura who regained normal ADAMTS13 levels after splenectomy.
Platelet counts, ADAMTS13 recovery, and infective complications were not significantly different between the 2 treatment groups.
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
Though all evaluated second-line treatments improved clinical outcomes, romiplostim was found to be the most effective at 6 months.
The VTE-BLEED risk score identified patients with pulmonary embolism at risk for in-hospital majorbleeding.
Among patients who underwent eculizumab withdrawal, 76.9% remained in remission during the course of the study.
The neural network developed in this study yielded a false-negative rate of 0.22%.
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Researchers reviewed outcomes from several phase 3 trials assessing the feasibility of fostamatinib for immune thrombocytopenia.
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.